Cargando…

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer

The purpose of this study was to evaluate the prognostic ability of early changes of total prostate specific antigen (tPSA), free PSA (fPSA), [−2]proPSA and the Prostate Health Index (PHI) following initiation of Abiraterone-therapy in men with castration resistant prostate cancer (mCRPC). In 25 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlack, Katrin, Krabbe, Laura-Maria, Fobker, Manfred, Schrader, Andres Jan, Semjonow, Axel, Boegemann, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037797/
https://www.ncbi.nlm.nih.gov/pubmed/27618028
http://dx.doi.org/10.3390/ijms17091520
_version_ 1782455816217952256
author Schlack, Katrin
Krabbe, Laura-Maria
Fobker, Manfred
Schrader, Andres Jan
Semjonow, Axel
Boegemann, Martin
author_facet Schlack, Katrin
Krabbe, Laura-Maria
Fobker, Manfred
Schrader, Andres Jan
Semjonow, Axel
Boegemann, Martin
author_sort Schlack, Katrin
collection PubMed
description The purpose of this study was to evaluate the prognostic ability of early changes of total prostate specific antigen (tPSA), free PSA (fPSA), [−2]proPSA and the Prostate Health Index (PHI) following initiation of Abiraterone-therapy in men with castration resistant prostate cancer (mCRPC). In 25 patients, PSA-subforms were analyzed before and at 8–12 weeks under therapy as prognosticators of progression-free-survival (PFS) and overall survival (OS). Comparing patients with a PFS < vs. ≥12 months by using Mann–Whitney–Wilcoxon Tests, the relative-median-change of tPSA (−0.1% vs. −86.8%; p = 0.02), fPSA (12.1% vs. −55.3%; p = 0.03) and [−2]proPSA (8.1% vs. −59.3%; p = 0.05) differed significantly. For men with ≤ vs. >15 months of OS there was a non-significant trend for a difference in the relative-median-change of fPSA (17.0% vs. −46.3%; p = 0.06). In Kaplan–Meier analyses, declining fPSA and [−2]proPSA were associated with a longer median PFS (13 months, 95% confidence interval (CI): 9.6–16.4 vs. 10 months, 95% CI: 3.5–16.5; p = 0.11), respectively. Correspondingly, decreasing fPSA and [−2]proPSA values indicated an OS of 32 months (95% CI: not reached (NR)) compared to 21 months in men with rising values (95% CI: 7.7–34.3; p = 0.14), respectively. We concluded that the addition of fPSA- and [−2]proPSA-changes to tPSA-information might be further studied as potential markers of early Abiraterone response in mCRPC patients.
format Online
Article
Text
id pubmed-5037797
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-50377972016-09-29 Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer Schlack, Katrin Krabbe, Laura-Maria Fobker, Manfred Schrader, Andres Jan Semjonow, Axel Boegemann, Martin Int J Mol Sci Article The purpose of this study was to evaluate the prognostic ability of early changes of total prostate specific antigen (tPSA), free PSA (fPSA), [−2]proPSA and the Prostate Health Index (PHI) following initiation of Abiraterone-therapy in men with castration resistant prostate cancer (mCRPC). In 25 patients, PSA-subforms were analyzed before and at 8–12 weeks under therapy as prognosticators of progression-free-survival (PFS) and overall survival (OS). Comparing patients with a PFS < vs. ≥12 months by using Mann–Whitney–Wilcoxon Tests, the relative-median-change of tPSA (−0.1% vs. −86.8%; p = 0.02), fPSA (12.1% vs. −55.3%; p = 0.03) and [−2]proPSA (8.1% vs. −59.3%; p = 0.05) differed significantly. For men with ≤ vs. >15 months of OS there was a non-significant trend for a difference in the relative-median-change of fPSA (17.0% vs. −46.3%; p = 0.06). In Kaplan–Meier analyses, declining fPSA and [−2]proPSA were associated with a longer median PFS (13 months, 95% confidence interval (CI): 9.6–16.4 vs. 10 months, 95% CI: 3.5–16.5; p = 0.11), respectively. Correspondingly, decreasing fPSA and [−2]proPSA values indicated an OS of 32 months (95% CI: not reached (NR)) compared to 21 months in men with rising values (95% CI: 7.7–34.3; p = 0.14), respectively. We concluded that the addition of fPSA- and [−2]proPSA-changes to tPSA-information might be further studied as potential markers of early Abiraterone response in mCRPC patients. MDPI 2016-09-09 /pmc/articles/PMC5037797/ /pubmed/27618028 http://dx.doi.org/10.3390/ijms17091520 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schlack, Katrin
Krabbe, Laura-Maria
Fobker, Manfred
Schrader, Andres Jan
Semjonow, Axel
Boegemann, Martin
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
title Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
title_full Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
title_fullStr Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
title_full_unstemmed Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
title_short Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
title_sort early prediction of therapy response to abiraterone acetate using psa subforms in patients with castration resistant prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037797/
https://www.ncbi.nlm.nih.gov/pubmed/27618028
http://dx.doi.org/10.3390/ijms17091520
work_keys_str_mv AT schlackkatrin earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer
AT krabbelauramaria earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer
AT fobkermanfred earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer
AT schraderandresjan earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer
AT semjonowaxel earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer
AT boegemannmartin earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer